MALP-2
Also known as: LP-2, Macrophage-Activating Lipopeptide-2, Macrophage‑activating lipopeptide‑2, MALP-2, MALP‑2, Mycoplasma fermentans lipopeptide 2, Pam2Cys‑SKPLG
Source MALP-2 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
MALP‑2 is a synthetic diacylated lipopeptide (Pam2Cys‑SKPLG) that potently stimulates innate immune cells via TLR2/6 and is used primarily as an immunostimulatory tool and experimental vaccine adjuvant.
Mechanism of Action
Activates Toll‑like receptor 2/6 heterodimer, triggering MyD‑dependent NF‑κB signaling and pro‑inflammatory cytokine release
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Macrophage activation researchImmunology (Research Tool)High
- Immune activationImmunologyModerate
- anti‑tumor immunityCancer ImmunotherapyLow
- Wound healing / angiogenesisDermatology / Regenerative MedicineLow
- Antitumor immunotherapyOncologyLow
- Mucosal vaccine adjuvantImmunology / VaccinologyModerate
- Sepsis / innate immune primingInfectious DiseaseLow
Contraindications
- Active sepsis or systemic inflammatory response syndromeInfectious Disease / Critical CareHigh
- Known hypersensitivity to lipopeptidesAllergy / ImmunologyHigh
- hypersensitivity to lipopeptidesAllergyModerate
- Systemic autoimmune diseaseImmunologicalHigh
Adverse Effects
- Fever / PyrexiaSystemicCommon
- Nausea / gastrointestinal discomfortGastrointestinalUncommon
- Cytokine release syndromeImmunologicRareSystemic inflammatory response from immune activation
- HypotensionCardiovascularRareLow blood pressure
- Local injection site inflammationLocal / DermatologicCommon
- Local inflammationLocalCommonInflammatory response at or near the administration site
- FeverSystemicCommonElevated body temperature
Drug Interactions
- Immunosuppressants (e.g., corticosteroids)Moderate
- Immunosuppressants (corticosteroids, cyclosporine)Moderate
- NSAIDsLowMay increase renal risk in susceptible patients
- Other TLR agonists (e.g., LPS, CpG)Moderate
Population Constraints
- Pediatric populationsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Pregnant animalsReproductiveRelative
Regulatory Status
- European UnionInvestigationalno clinical approval
- United StatesInvestigationalused only in pre‑clinical research
- United KingdomInvestigationalresearch use only
Not approved for human therapeutic use; employed in pre‑clinical studies only.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is MALP-2?
MALP‑2 is a synthetic diacylated lipopeptide (Pam2Cys‑SKPLG) that potently stimulates innate immune cells via TLR2/6 and is used primarily as an immunostimulatory tool and experimental vaccine adjuvant.
What is MALP-2 used for?
MALP-2 is educationally associated with: Vaccine adjuvant, Macrophage activation research, Immune activation, anti‑tumor immunity, Wound healing / angiogenesis, Antitumor immunotherapy, Mucosal vaccine adjuvant, Sepsis / innate immune priming. Educational only — not medical advice.
How is MALP-2 administered?
Recorded routes of administration: Intranasal, Intraperitoneal, Intravenous, Oral, Subcutaneous, Topical.
What are the potential side effects of MALP-2?
Reported adverse effects include: Fever / Pyrexia, Nausea / gastrointestinal discomfort, Cytokine release syndrome, Hypotension, Local injection site inflammation, Local inflammation, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid MALP-2?
Recorded contraindications: Active sepsis or systemic inflammatory response syndrome, Known hypersensitivity to lipopeptides, hypersensitivity to lipopeptides, Systemic autoimmune disease. Consult a qualified clinician before use.